CRISPR Therapeutics has crossed a key technical hurdle by surpassing an 80 Relative Strength Rating. The biotech company’s performance signals notable momentum in a competitive market space.

Salesforce’s recent share price of $236.58 and solid fundamentals have drawn attention from bullish investors. A closer look at its trailing P/E of 34.72 and forward P/E of 18.87 reveals a strong case for growth in the evolving cloud-based CRM market.